In today’s briefing:
- US Banks – USD13 Trillion in Loans, First Time Ever, as at Week 30 July
- APAC Healthcare Weekly (Aug 10) – Chugai, Hisamitsu, Wuxi XDC, CSPC Pharma, Junshi Bio, Hanmi Pharma
US Banks – USD13 Trillion in Loans, First Time Ever, as at Week 30 July
- US banks have saw loans rise from USD2 tr to USD13 tr from 1990 to newest release; it is 1st time we have seen USD13,005bn in loans
- US banks are still seeing growth rates YoY at over 4%, with this pace of growth now seen for the past 5 weeks of data
- Even where the Senior Loan Officer Survey is mixed (not in this report), US banks are seeing good lending growth, and benign provisions
APAC Healthcare Weekly (Aug 10) – Chugai, Hisamitsu, Wuxi XDC, CSPC Pharma, Junshi Bio, Hanmi Pharma
- Eli Lilly announced positive topline results from Phase 3 trial, evaluating orforglipron, discovered by Chugai. Hisamitsu Pharmaceutical initiated Phase 3 trial of HP-6050, a transdermal formulation for sedation in Japan.
- WuXi XDC completed GMP release of its new drug product facility in China. CSPC Pharmaceutical’s application for marketing approval of Semaglutide Injection has been accepted by the NMPA of China.
- Junshi Biosciences’s indication expansion application for toripalimab for treatment of urothelial carcinoma has been accepted in China. Hanmi Pharma advances HM17321, a first-in-class obesity therapy, into global Phase 1 trials.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
